Literature DB >> 18456536

The significance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes.

Harvey Moldofsky1.   

Abstract

The clinical focus of rheumatologists on the widespread pain and numerous tender points in specific anatomic regions in their patients who show no evidence for disease pathology has lead to the characterization of such peripheral symptoms as a specific disorder of the musculoskeletal system, now commonly known as fibromyalgia. This rheumatologic diagnostic entity has resulted in relative inattention to an understanding of their patients' common complaints of unrefreshing sleep, chronic fatigue and psychological distress. Experimental evidence from humans and animal studies indicate that there is an inter-relationship of disturbances in the physiology of the sleeping-waking brain with the widespread musculoskeletal pain, chronic fatigue, and psychological distress in patients with hitherto unexplained pain/fatigue illnesses, e.g., fibromyalgia and chronic fatigue syndromes. The emerging knowledge of the dysfunction of the nervous system in such patients has lead to the study of novel medications that affect neurotransmitter functions, e.g., pregabalin, serotonin/noradrenaline compounds and sodium oxybate that are shown to improve many of the symptoms of such patients.

Entities:  

Mesh:

Year:  2008        PMID: 18456536     DOI: 10.1016/j.jbspin.2008.01.021

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  20 in total

1.  Sleep apnea symptoms and risk of temporomandibular disorder: OPPERA cohort.

Authors:  A E Sanders; G K Essick; R Fillingim; C Knott; R Ohrbach; J D Greenspan; L Diatchenko; W Maixner; R Dubner; E Bair; V E Miller; G D Slade
Journal:  J Dent Res       Date:  2013-05-20       Impact factor: 6.116

Review 2.  The role of sleep in pain and fibromyalgia.

Authors:  Ernest H S Choy
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

3.  Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome.

Authors:  Todd J Swick
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-08       Impact factor: 5.346

Review 4.  Fibromyalgia: evolving concepts over the past 2 decades.

Authors:  Mary-Ann Fitzcharles; Peter A Ste-Marie; John X Pereira
Journal:  CMAJ       Date:  2013-05-06       Impact factor: 8.262

Review 5.  Fibromyalgia: from pathophysiology to therapy.

Authors:  Tobias Schmidt-Wilcke; Daniel J Clauw
Journal:  Nat Rev Rheumatol       Date:  2011-07-19       Impact factor: 20.543

6.  Sleep-stage dynamics in patients with chronic fatigue syndrome with or without fibromyalgia.

Authors:  Akifumi Kishi; Benjamin H Natelson; Fumiharu Togo; Zbigniew R Struzik; David M Rapoport; Yoshiharu Yamamoto
Journal:  Sleep       Date:  2011-11-01       Impact factor: 5.849

7.  Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial.

Authors:  Barth L Wilsey; Scott Fishman; Chin-Shang Li; Jeanna Storment; Anthony Albanese
Journal:  Pharmacol Biochem Behav       Date:  2009-08-04       Impact factor: 3.533

Review 8.  [Fibromyalgia].

Authors:  M Späth
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

Review 9.  From descending pain modulation to obesity via the medullary raphe.

Authors:  Peggy Mason
Journal:  Pain       Date:  2010-11-18       Impact factor: 6.961

10.  [Treatment of fibromyalgia syndrome with gamma-hydroxybutyrate : A randomized controlled study].

Authors:  E Reuter; S Tafelski; K Thieme; C West; U Haase; L Beck; M Schäfer; C Spies
Journal:  Schmerz       Date:  2017-04       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.